I was thinking this before you posted, but it would be interesting to see if current patients (preferably mono patients or combo patients not using toxic drugs) have NASH, liver fibrosis, metastatic cancer, or other CCR5-linked diseases?

I agree with you other than combo and mono is mostly not that involved right now (combo needs BLA filed and mono pending FDA approval) so why not get future indications teed up and ready for trials at relatively low costs? I don't think CYDY intends to initiate these trials unless a BP is paying for them or our financing concerns are resolved.